President Trump received mostly the same treatment as anyone would get for COVID-19, except for one experimental drug and the speed of his care. USA TODAY
Since President Donald Trump's COVID-19 diagnosis and hospitalization, health care professionals have voiced concernsregarding his broad medical regimen, which include steroid dexamethasone and Gilead's remdesivir. One treatment in particular, an experimental antibody drug from Regeneron Pharmaceuticals, is drawing criticism on social media.
"So it turns out the monoclonal antibodies Trump is on are from fetal stem cells. So Trump is being treated/saved with dead babies," reads a Twitter post shared on the Facebook group Dogs for Democracy.
The tweet goes on to call out Republicans,Supreme Court nominee Judge Amy Coney Barrettand anti-abortion activists.
Fact or fiction: We're fact checking the news and sending it to your inbox. Sign up to get that here.
A follow-up tweet containing a link to Regeneron's official position statement on stem cell research is provided as evidence for the claim.
While the Facebook post sharing the tweet has not received significant attention on the platform, it has gone viral on Twitter, gaining more than 347,000 likes and 107,000 retweets; similar tweets have also gone viral, including one from Rep.Ted Lieu, D-Calif.
USA TODAY has reached out to the administrators of the Dogs for Democracy Facebook group for further comment.
When the human body is invaded by a foreign pathogen be it a bacterium, virus, fungusor parasite Y-shaped proteins called antibodies are formed.They circulate through the body to sequesterand alert other immune chemicals and cells to destroy the pathogen, much like a search-and-destroy system.
The secret to fighting COVID-19 could be in recovered patients. Here's how antibodies could lead to a treatment for those fighting coronavirus. USA TODAY
Antibodies form the basis of "adaptive" immunity because they are genetically engineered, in a sense, by the body to recognize certain pathogens. This genetic engineering occurs within white blood cells called B cells, which manufactureand displaythe proteinson the cell surface, by way of genes rearranging like a set of numbers rearrangingto form different sequences or patterns.
Because this rearrangement is random, there is no telling what kind of specificity an antibody will exhibit or whether it will be biologically useful. Only if a B cell meets the right pathogen at the right time will it then activate and secrete its bespoke antibody. The activated B cell will also go on to clone itself through a process called clonal expansion, which helps mount an effective immune response by spawning vast quantities of antibodyand memory B cells (B cells which will remember the encounter for any future run-ins)as well as activating other immune cells.
Regeneron's experimental antibody "cocktail,"known as REGN-COV2, is a combination of two monoclonal antibodies (monoclonal referring to a specific B cell clone). These antibodies, REGN10933 and REGN10987, are engineered to lock on to SARS-CoV-2's spike protein, preventing it from interacting with its target on the host cell surface, the ACE2 receptor.
REGN-COV2 began its first clinical trial in June and is now in four late-stage clinical trials estimated to recruit at least11,000 participants combined, according to Genetic Engineering and Biotechnology News.
The antibody therapy has so far shown it's able to reduce SARS-CoV-2 viral loads and disease in experiments with golden hamsters and rhesus macaques. Findings presented last month from Regeneron's preliminary experiments in nonhospitalized, SARS-CoV-2 positive patients ranging from asymptomatic to moderate cases also showed reduced viral loads. However, more studies are needed to see how truly effective REGN-COV2 will be.
Fact check: Satirical post falsely claims Trump would be fine if he hadn't gotten tested
Fact check: Trump's hospital records, weight have not been released
Plasma cell producing antibodies, attacking coronavirus.(Photo: Floriana, Getty Images/iStockphoto)
Alexandra Bowie of Regeneron told news aggregation platform Heavy in an October email that REGN-COV2 was not made with human embryonic stem cells.
"This particular discovery program (REGN-COV2) did not involve human stem cells or ESCs," Bowie wrote.
The statement shared on Twitteris simply Regeneron's official position on stem cell research in general and bears no relation to, or explanation of, how REGN-COV2 is made. Bowie also confirmed this with Heavy.
It is unclear why Regeneron released an official statement in April. In an email to USA TODAY, Bowie did not clarify the timing, only alluding to the fact it was a common practice among pharmaceutical companies and that Regeneron sought transparency.
"Like many biopharma companies that conduct scientific research (see Pfizer, J&J, for instance), we have a general position statement on stem cell use,"Bowie said. "We share this and other similar statements in the interest of transparency and to help educate people on the steps we take to conduct our business responsibly."
While REGN-COV's monoclonal antibodies do appear to be derived from a B cell lineisolated from a human donor who recovered from SARS-CoV-2 and an immunized mouse engineered to have a human immune system,USA TODAY did note a fetal-derived cell linementioned in Regeneron's early research.
In supplementary material to a paper published in June in the journal Science, HEK293T cells an immortalized epithelial cell line (cellsnot normally immortal butaltered to be so via spontaneous mutation or in the lab)derived from embryonic kidney cellsobtained in 1972 were described as "briefly" used to create SARS-CoV-2-like viral particles to test mouse and human-derived antibodies against.
Bowie affirmed HEK293T cells were used but reiterated stem cells were not.
"This particular discovery program (REGN-COV2) did not involve human stem cells or ESCs," she wrote. "The293T cell line was originally derived from human embryonic kidney cells but is an immortalized epithelial cell so not a stem cell. These cells were transfected and used in production of a pseudoparticle that mimics the virus Spike protein and allowed us to test neutralization ability of our antibodies against the virus."
Fact check: Satirical post falsely claims COVID-19 is no worse than the flu and affects virtually no one
We rate this claim FALSE because it is not supported by our research.The experimental antibody therapy Trump received was not directly made from fetal or embryonic stem cells, rather antibodies obtained from SARS-CoV-2 human survivors and immunized mice engineered with a human immune system. Regeneron's official statement released in April, cited on Twitter as a basis for the claim, is a general position on stem cell research and is unrelated to how the antibody therapy is actually made. However, an embryonic-derived cellline, albeit not a stem cell, does appear to have been involved at least in the early stages of Regeneron's testing process, according to supplementary material published in June. The HEK293T cellsused are an immortalized cellline derived from embryonic kidney cells but are not stem cells themselves.
Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.
Our fact check work is supported in part by a grant from Facebook.
This fact check is available at IFCNs 2020 US Elections FactChat #Chatbot on WhatsApp. Click here, for more.
Continue reading here:
- Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily - July 31st, 2021
- Colin Jackson health: Im in constant pain Athlete to undergo stem cell therapy to help - Express - July 31st, 2021
- The Talking Man: New Advances In Regenerative Medicine - Forbes - July 31st, 2021
- Medipost's clinical trial approved to evaluate efficacy of knee osteoarthritis treatment - Aju Business Daily - July 31st, 2021
- A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with... - July 31st, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - July 31st, 2021
- Treatment Approaches for Patients With R/R DLBCL - Targeted Oncology - July 31st, 2021
- Global $57.4 Billion Cell And Gene Therapy Manufacturing Market to 2028 - Rising Pressure on Drug Developers/Manufacturers to Meet the Growing Market... - July 31st, 2021
- Acute Myeloid Leukemia Fungal Infections: Types and Treatment - Healthline - July 31st, 2021
- Overview of DLBCL - Targeted Oncology - July 31st, 2021
- Roundtable Discussion: Participants Evaluate the Use of Transplant and MRD in Newly Diagnosed Multiple Myeloma - Targeted Oncology - July 31st, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market: Allogeneic transplant is projected to continue to hold a dominant market share - BioSpace - July 27th, 2021
- Researchers develop a cell culture test to detect substances that harm the placenta and embryo - News-Medical.net - July 27th, 2021
- FDA Approves KEYTRUDA (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With... - July 27th, 2021
- Cryopreservation of Unrelated Donor SCTs Safe, Effective in Patients Who Underwent HSCT - Hematology Advisor - July 27th, 2021
- Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer - The Institute of Cancer Research, London - The... - July 25th, 2021
- Study proposes repurposed drug to treat COVID-19 - The Hindu - July 25th, 2021
- Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema - News-Medical.Net - July 25th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 23rd, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 23rd, 2021
- Regenerative Medicine provides new hope and healing - Summit Daily News - July 23rd, 2021
- Emphysema Reversed in Mice Given Injection of Healthy Pulmonary Endothelial Cells - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Nelson: Gimpy girls have different means of recovery - Watertown Public Opinion - July 23rd, 2021
- Gene Therapy Protects Optic Nerve Cells and Vision in Mice with Retinal Injury and Glaucoma - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Has COVID-19 Opened up the Route to Market for Cell and Gene Therapy? - Pharmaceutical Executive - July 23rd, 2021
- Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments - OncLive - July 23rd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 23rd, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 21st, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 21st, 2021
- Stem Cell Therapy Gets Fast Track Status for Parkinson Disease - Monthly Prescribing Reference - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Donating a chance at life: Kokomo teacher donates stem cells to 75-year-old woman through Be the Match - Kokomo Perspective - July 21st, 2021
- Young Patients With Multiple Myeloma May Benefit From Tandem Autologous Hematopoietic Stem Cell Transplantation - Hematology Advisor - July 21st, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 21st, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 21st, 2021
- YOUR HEALTH: Finding cures by tracking cells - WQAD.com - July 21st, 2021
- Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer - News-Medical.Net - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 17th, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 17th, 2021
- For Patients with HIV and Cancer, a Multidisciplinary Treatment Approach is Critical - Targeted Oncology - July 17th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 15th, 2021
- The Memphis Institute of Regenerative Medicine Rebrands To Reflect Statewide Reach - UTHSC News - July 15th, 2021
- Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma - OncLive - July 15th, 2021
- TiTAN-1 Trial of GEN-011 Initiates Treatment in Patients With Solid Tumors - Targeted Oncology - July 15th, 2021
- Saving a life, fixing the world - The Jewish Standard - July 15th, 2021
- Exosome spray may be better able to heal damaged hearts - New Atlas - July 15th, 2021
- Prime Medicine uncloaks with $315M to push 'search and replace' gene editing treatments - FierceBiotech - July 13th, 2021
- Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS - OncLive - July 13th, 2021
- U.S. Stem Cell, Inc The New Generation Company In The ... - July 11th, 2021
- Stem Cell Therapy - Stemedix | Regenerative Medicine Also ... - July 11th, 2021
- FIRM, CAS further cooperate to advance reproductive medicine research_china.org.cn - China.org.cn - July 11th, 2021
- England's drug price watchdog rejects Orchard's groundbreaking gene therapy after first round of talks - FiercePharma - July 11th, 2021
- ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma - Targeted Oncology - July 9th, 2021
- Gene therapy for sickle cell disease: progress and competition - BioPharma Dive - July 9th, 2021
- Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere... - July 9th, 2021
- Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma - OncLive - July 9th, 2021
- More than $25m awarded to Monash researchers for vital medical research - Monash University - July 9th, 2021
- Magnetically-guided delivery of therapeutic stem cells into the brain - Advanced Science News - July 7th, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Stem cell therapy could make significant impact as opioid alternative - The Pharma Letter - July 7th, 2021
- Institute for Stem Cell Biology and Regenerative Medicine ... - July 5th, 2021
- Home - World Stem Cell Summit - July 5th, 2021
- Stem Cell Therapy & Regenerative Medicine Clearwater, FL ... - July 5th, 2021
- Ethical Issues in Stem Cell Research - July 5th, 2021
- Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com - Business Wire - July 3rd, 2021
- Regenerative Therapy Makes Headway in HF ... in the Right Patients - MedPage Today - July 3rd, 2021
- A New Era For FDA Regulation Of Cell And Tissue Products - Law360 - July 3rd, 2021
- Multiple myeloma treatment: Newest options, drugs, and more - Medical News Today - July 3rd, 2021
- Anti-CD22 CAR-T cell therapy as a salvage treatment - OTT | OTT - Dove Medical Press - July 3rd, 2021
- Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma - AJMC.com Managed Markets Network - July 3rd, 2021
- The cell therapy manufacturing market is projected to reach USD 14.5 billion by 2030, growing at - GlobeNewswire - July 3rd, 2021
- Cellular Model of a Developing Mouse Is Built With Spatial Resolution - Technology Networks - July 3rd, 2021
- Gene editor injected into the body treats disease - Science - July 3rd, 2021
- Philippe Moreau, MD, on the Implications of Daratumumab Maintenance for Newly Diagnosed Multiple Myeloma - Cancer Network - July 3rd, 2021
- Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial - The... - July 1st, 2021
- New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications -... - July 1st, 2021
- XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma - PRNewswire - July 1st, 2021
- MCL Treatment: Differences Exist Between Trial-Based Recommendations and Real-World Care - Curetoday.com - July 1st, 2021
- Harton improving with stem cell treatment | Sports | thefacts.com - Brazosport Facts - June 29th, 2021
- Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or... - June 29th, 2021